News & Updates

Bimekizumab outperformed risankizumab in the American College of Rheumatology ≥50 percent response criteria (ACR50) among patients with active psoriatic arthritis (PsA) in the phase IIIb BE BOLD trial – the first head-to-head PsA study to demonstrate superiority for a joint-focused primary endpoint. 

Prenatal paracetamol exposure is not associated with an increased risk of attention‑deficit/ hyperactivity disorder (ADHD) or autism spectrum disorder (ASD), according to researchers from the University of Hong Kong (HKU).